The earnings call highlighted Regeneron's strong financial performance, driven by key products and a robust pipeline. However, challenges such as competitive pressure on EYLEA and increased R&D expenses were noted. The company's strategic capital allocation and pipeline advancements position it well for future growth.

Company Guidance

During Regeneron Pharmaceuticals' Fourth Quarter 2024 Earnings Conference Call, the company provided guidance for 2025, highlighting several key metrics and strategic focuses. Regeneron anticipates significant growth opportunities driven by new product launches and enhancements, such as the EYLEA HD prefilled syringe and expanded dosing flexibility, which are expected to strengthen its market position. They forecast 2025 R&D expenses to range between $5 billion and $5.2 billion, reflecting investments in late-stage pipeline programs, including Factor XI antibodies and oncology assets. SG&A expenses are projected to be between $2.55 billion and $2.7 billion, with gross margins on net product sales expected to be 87% to 88%. Regeneron also introduced a quarterly dividend of $0.88 per share and announced an additional $3 billion share repurchase authorization, highlighting their commitment to returning capital to shareholders while maintaining strategic investments in R&D to drive long-term growth.

Strong Revenue Growth

Regeneron reported a 10% revenue growth in Q4 2024, driven by key franchises including Dupixent, Libtayo, EYLEA, and EYLEA HD.

Dupixent's Transformative Impact

Dupixent continues to lead with over 1 million patients worldwide, maintaining leadership in new prescriptions across all approved indications.

EYLEA HD Expansion

EYLEA HD demonstrated best-in-class clinical profile, with plans to enhance its label for broader indications and flexible dosing.

Libtayo's Blockbuster Status

Libtayo achieved blockbuster status with global net sales of $1.2 billion in 2024, showing strong growth in non-melanoma skin cancers and lung cancer.

Innovative Pipeline

Regeneron's pipeline includes potential approvals for linvoseltamab, odronextamab, and pivotal data for several programs, positioning it for long-term growth.

Capital Allocation Strategy

Regeneron announced a quarterly cash dividend and increased share repurchase authorization by $3 billion, demonstrating commitment to returning capital to shareholders.

---

Regeneron (REGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

REGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 01, 2025	2025 (Q1)	9.55 / -	9.55	―	―	―
Feb 04, 2025	2024 (Q4)	11.28 / 12.07	11.86	1.77% (+0.21)
Oct 31, 2024	2024 (Q3)	11.70 / 12.46	11.59	7.51% (+0.87)
Aug 01, 2024	2024 (Q2)	10.62 / 11.56	10.24	12.89% (+1.32)
May 02, 2024	2024 (Q1)	10.17 / 9.55	10.09	-5.35% (-0.54)
Feb 02, 2024	2023 (Q4)	10.73 / 11.86	12.56	-5.57% (-0.70)
Nov 02, 2023	2023 (Q3)	10.68 / 11.59	11.14	4.04% (+0.45)
Aug 03, 2023	2023 (Q2)	9.85 / 10.24	9.77	4.81% (+0.47)
May 04, 2023	2023 (Q1)	9.52 / 10.09	11.49	-12.18% (-1.40)
Feb 03, 2023	2022 (Q4)	10.25 / 12.56	23.72	-47.05% (-11.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

REGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 04, 2025	$666.85	$697.05	+4.53%
Oct 31, 2024	$922.79	$838.20	-9.17%
Aug 01, 2024	$1079.19	$1093.14	+1.29%
May 02, 2024	$903.48	$937.61	+3.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---